Alvotech Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Robert Wessman

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	98.3%
Permanencia del CEO	1.5yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	3.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Robert Wessman en comparación con los beneficios de Alvotech?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$494m
Dec 31 2023	US$2m	US$1m	-US$552m
Sep 30 2023	n/a	n/a	-US$596m
Jun 30 2023	n/a	n/a	-US$416m
Mar 31 2023	n/a	n/a	-US$713m
Dec 31 2022	US$740k	n/a	-US$514m

Compensación vs. Mercado: La compensación total ($USD1.52M) de Robert está en línea con el promedio de empresas de tamaño similar en el mercado IS ($USD1.79M).

Compensación vs. Ingresos: La compensación de Robert ha aumentado mientras la empresa no es rentable.

CEO

Robert Wessman (54 yo)

1.5yrs

Permanencia

US$1,517,000

Compensación

Mr. Robert Wessman serves as Chief Executive Officer of Alvotech since January 1, 2023. He Founded Alvotech in 2013 and serves as its Executive Chairman and Member of the Board of Directors since January 2...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Wessman	CEO, Founder & Executive Chairman	1.5yrs	US$1.52m	sin datos
Faysal Kalmoua	COO & Director	less than a year	sin datos	0% $ 0
Joel Morales	Chief Financial Officer	4.4yrs	sin datos	0.035% $ 163.5m
Giedrius Zunda	Chief Technical Officer	no data	sin datos	sin datos
Joseph McClellan	Chief Scientific Officer	4.8yrs	sin datos	0.055% $ 259.6m
Tanya Zharov	General Counsel	1.5yrs	sin datos	0% $ 0
Jenny Steingrimsdottir	Vice President of People & Culture	less than a year	sin datos	sin datos
Anil Okay	Chief Commercial Officer	6yrs	sin datos	sin datos
Ming Li	Chief Strategy Officer	4.5yrs	sin datos	sin datos
Christina Siniscalchi	Chief Quality Officer	less than a year	sin datos	sin datos

1.5yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ALVO no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Wessman	CEO, Founder & Executive Chairman	5.5yrs	US$1.52m	sin datos
Faysal Kalmoua	COO & Director	4.1yrs	sin datos	0% $ 0
Hjorleifur Palsson	Director	no data	sin datos	sin datos
Linda McGoldrick	Independent Non-Executive Director	2.1yrs	US$81.00k	0.0038% $ 17.9m
Lisa Graver	Non-Executive Director	2.1yrs	US$71.00k	0.0038% $ 17.9m
Tomas Ekman	Non-Executive Director	5.5yrs	sin datos	sin datos
Arni Hardarson	Non-Executive Director	2.1yrs	sin datos	sin datos
Richard Davies	Independent Non-Executive Deputy Chairman	5.5yrs	US$156.00k	0.38% $ 1.8b
Ann Merchant	Independent Non-Executive Director	2.1yrs	US$113.00k	0.0038% $ 17.9m

3.1yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de ALVO se considera experimentada (3 años de antigüedad promedio).

Alvotech Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Alvotech Appoints Hjörleifur Pálsson as Director

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech Announces Executive Changes

Alvotech Announces Changes to the Leadership Team

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Announces Executive Changes, Effective January 1, 2023

Recent updates

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$2.43 loss per share (vs US$2.60 loss in FY 2022)

Alvotech Announces Executive Changes

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, Proposed Biosimilar for Simponi and Simponi Aria

Alvotech to Report Q1, 2023 Results on May 18, 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$2.60 loss per share (vs US$0.92 loss in FY 2021)

European Medicines Agency Accepts a Marketing Authorization Application for AVT04 of Alvotech

Alvotech Announces European Medicines Agency (EMA) Accepts Marketing Authorization Application for AVT04

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech Initiates Pharmacokinetic Study for AVT05

Alvotech and Teva Announces Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech Announces FDA Grant A New Biosimilar User Fee Amendment

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Alvotech Announces Executive Changes, Effective January 1, 2023

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Third quarter 2022 earnings released

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Less than half of directors are independent

Alvotech Announces Australian Marketing Authorization for AVT02, A Biosimilar to Humira

Alvotech to Report Nine Months, 2022 Results on Nov 15, 2022

Alvotech Announces Executive Changes

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech Initiates Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech to Report Q2, 2022 Results on Aug 31, 2022

Alvotech Initiates Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Alvotech Expands its Board of Directors as Part of Transition from Private to Publicly Traded Company

Alvotech Initiates Patient Study for AVT06

No independent directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media